# Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

> **NCT03682770** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 148 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo matching dupilumab
- **DRUG:** AR101

## Key facts

- **NCT ID:** NCT03682770
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-03
- **Primary completion:** 2020-10-16
- **Final completion:** 2021-07-23
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03682770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03682770, "Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03682770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*